Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

DISEASE CHARACTERISTICS: Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer Recurrent or progressive disease Received at least 1 prior platinum-based chemotherapy regimen containing carboplatin, cisplatin, or another organoplatinum compound for primary disease May include high-dose therapy, consolidation, or extended therapy after surgical or non-surgical assessment No brain metastases or leptomeningeal involvement PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,000/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 8.0 g/dL Hepatic: AST and ALT no greater than 2.5 times upper limit of normal Bilirubin no greater than 1.8 mg/dL Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: LVEF greater than 50% by radionuclide ventriculogram or two-dimensional echocardiogram No peripheral vascular disease requiring surgical management No prior myocardial infarction No congestive heart failure No orthostatic hypotension No acute ischemia or significant conduction abnormality (bifascicular block, defined as left anterior hemiblock with right bundle branch block, second or third degree AV blocks) as evidenced by electrocardiogram No prior cerebrovascular event Other: No peripheral neuropathy grade 2 or greater No other serious medical or psychiatric illness Not pregnant Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics No more than 2 prior regimens for recurrent disease, including 1 non-platinum containing regimen At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered Endocrine therapy: At least 1 week since prior hormonal therapy directed at primary tumor Concurrent hormone replacement therapy allowed Radiotherapy: Not specified Surgery: See Disease Characteristics At least 2 weeks since prior major surgery